Drug Retail

Mangoceuticals

Mangoceuticals released FY2025 Annual Earnings on April 1 (EST), actual revenue USD 456.02K, actual EPS USD -2.17

Mangoceuticals released FY2025 Q4 earnings on April 1, 2026 (EST), with actual revenue of USD 94.36K and EPS of USD -0.2159

Nasdaq-listed Mangoceuticals Plans to Launch a $100 Million SOL Digital Asset Treasury

Mangoceuticals released FY2025 9 Months Earnings on November 14 EST, actual revenue USD 361.66 K, actual EPS USD -2.2826

Mangoceuticals released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 84.25K, actual EPS USD -0.69

Mangoceuticals released FY2025 Semi-Annual Earnings on August 14 (EST), actual revenue USD 277.42K, actual EPS USD -1.4081

Mangoceuticals released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 168.11K, actual EPS USD -0.5424

Mangoceuticals released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 109.31K, actual EPS USD -1.0536

Mangoceuticals Inc. Acquires Smokeless Technology Corp.'s Intellectual Property

Mangoceuticals released FY2024 earnings on March 20 (EST), actual revenue USD 615.87K, actual EPS USD -4.8046

Mangoceuticals released FY2024 Q4 earnings on March 20 (EST) with actual revenue of 105.25K USD and EPS of -1.0762 USD

Mangoceuticals released FY2024 Q3 earnings on November 14, 2024 (EST), actual revenue USD 133.37 K, actual EPS USD -1.1387

Mangoceuticals released FY2024 9 Months Earnings on November 14 (EST), actual revenue USD 510.63K, actual EPS USD -4.0164

Mangoceuticals released FY2024 Semi-Annual earnings on August 14 (EST), actual revenue USD 377.26K, actual EPS USD -2.8712

Mangoceuticals obtains patent certificate for respiratory disease technology

Mangoceuticals' Stock Price Doubles to $0.60, Plans to Launch Oral GLP-1 Drug

Mangoceuticals released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 214.1K, actual EPS USD -1.5035

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MGRX

SBIO

LABU

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Health Care Select Sector SPDR

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Earnings Watch

Mangoceuticals | 10-Q: FY2026 Q1 Revenue: USD 67.86 K

Mangoceuticals | 10-K: FY2025 Revenue: USD 456.02 K

Mangoceuticals reported annual revenue of $0.456 million, down from $0.616 million the previous year, with a net loss of $(20.643) million, compared to $(8.707) million last year. The basic and diluted loss per share was $(2.17). The revenue decline was attributed to issues during a platform migration and relaunch, alongside increased operational costs. The company is focusing on telemedicine services and investing in technology and staffing to support future growth.

Mangoceuticals 10-K: Revenue $0.456M, EPS loss $(2.17)

Mangoceuticals, Inc. (MGRX) has announced a delay in filing its Form 10-K for the fiscal year ending December 31, 2025, originally due on March 31, 2026. The delay is due to the external auditor needing more time for review. The company expects to file the report within 15 days of the original deadline and does not anticipate significant changes in its financial results. CEO Jacob D. Cohen signed the notification, emphasizing management's commitment to compliance and timely reporting.

Tip Ranks

Mangoceuticals Delays Annual 10-K Yearly Filing

ASTC

ITRM

MKDW

UGRO

In the past hour, the overall market in the U.S. stock market has shown significant divergence, with technology stocks and small-cap stocks performing particularly well. Astrotech's surge of 167.93% has attracted widespread attention in the market, driving the activity of related technology stocks. Meanwhile, several stocks in the pharmaceutical sector have also performed well, with Iterum Therap and MKD Tech rising by 106.74% and 60.08%, respectively, and their trading volumes significantly increasing, indicating strong capital interest. In contrast, some green energy and financial stocks have faced considerable pressure, with Roma Green Finance dropping sharply by 58.57%, reflecting market sentiment fluctuations. The stock with the largest movement in the past hour, Astrotech, saw its price soar to 167.93% in a short period, reaching a new 60-day high, with market sentiment running high and noticeable capital inflow. The strong performance of this stock seems to have attracted a large amount of short-term capital, energizing the entire technology sector. Strong stocks: 1. Iterum Therap: up 106.74%, with increased trading volume, driven by optimistic market sentiment about its future prospects, leading to a rapid rise in stock price. 2. MKD Tech: up 60.08%, with an influx of short-term capital making the stock stand out during the session, attracting the attention of many investors. 3. Greenland Energy: up 52.26%, this stock has been favored by the market against the backdrop of energy transition, with significantly increased trading volume

Price Alert

Astrotech

Iterum Therap

MKD Tech

Roma Green Finance

Greenland Energy

Urban-Gro

EpicQuest Edu

Quantum Biopharma

Southland

DNA X

System1

Lantern Pharma

Ridgetech

Next Tech

Robin Energy - WI

Sobr Safe

Fast Track

High-Trend

Innovate

Turbo Energy SA

22nd Century

TruGolf

Cognition Therapeutics

Agape ATP

Polaryx Therapeutics

Shuttle Pharmaceuticals

United Therap

MMTEC

Paranovus ENT Tech

Applied Optoelectronics

U Power

Swarmer

Founder

Boxlight

Jinxin Tech

Delixy

Abits

Luda Tech

Jaguar Uranium

Aeries Tech

AEON Biopharma, Inc.

Sysco

MOUNTAIN LAKE ACQUISITION CORP COM USD0.0001 CL A (SUB/RIGHTS) 15/11/28

FGI Industries

Century Aluminum

Beachbody

Rani Therapeutics

Chanson

Alcoa

NextTrip

Trio Petroleum

Enigmatig

SUNation Energy

Falcon Beyond Global

Kopin

Solo Brands

Opendoor Tech Series K - CW26

Veritone

Robinhood Ventures Fund I

Corvex

Bloom Energy

Newsmax

PRF Tech

Insight Molecular Diagnostics

Boqii

ImageneBio

Cibus

Globavend

ENvue Medical

Axe Compute

Origin Agritech

Carvana

Texxon

Applied Digital

Fabrinet

Streamex

ImmunityBio

EON Resources

ITERUM THERAPEUTICS PLC

U.S. stock market movement update: Astrotech surged 167.93%, Iterum Therap rose 106.74%, with multiple stocks experiencing increased trading volume; Roma Green Finance fell 58.57%, and Skycorp Solar dropped 45.70%!

BIAFW

On March 24, 2026, urban-gro, bioAffinity Technologies, and Mangoceuticals are highlighted as the top penny stocks to watch, according to TipRanks' Penny Stock Screener. These stocks are priced at $5 or below and typically have a market cap under $300 million. The screener helps investors filter stocks based on various criteria, including Dollar Volume, which is the total value of shares traded. The selection is based on the highest Dollar Volume as of March 23 market close.

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM)

iShares US Medical Devices

bioAffinity Tech

3 Penny Stocks to Watch Now, 3/24/26

GMEX

Mangoceuticals pre-market down 11.74%; GMEX Robotics pre-market down 10.71%; Paranovus ENT Tech pre-market up 70.27%; Urban-Gro pre-market up 28.62%; Netgear pre-market up 16.46%

GMEX Robotics

Pre-market hot trades in US stocks: Mangoceuticals down 11.74% pre-market; GMEX Robotics down 10.71% pre-market

Mangoceuticals Inc. (NASDAQ:MGRX) stock has doubled, rising 109.51% to $0.34, despite no new news. The surge follows a lawsuit against former partner Clarity Ventures for over $73 million, alleging failure to deliver a functional platform. Clarity has countered with unpaid invoice claims. In response, Mangoceuticals has developed its own telehealth and eCommerce platform, enhancing operations. Additionally, the company's testosterone replacement therapy (TRT) program has seen a 336% sales increase since launch, with management expecting it to drive future growth.

benzinga_article

Mangoceuticals Stock Doubles After Texas Lawsuit

QQWZ

.DJI

.NDX

The Chicago Fed's National Activity Index decreased to -0.11 in February from 0.20 in January, falling short of the expected -0.04. The three-month moving average rose slightly to -0.01. Out of 85 indicators, 31 contributed positively while 54 negatively, with 31 improving and 53 deteriorating during the month.

- The Chicago Federal Reserve Bank's National Activity Index decreased to minus 0.11 in February from 0.20 in January.  
- This reading was below the expected value of 0.04 as per Bloomberg's survey.  
- The three-month moving average slightly improved to minus 0.01 from minus 0.02, with 31 indicators contributing positively and 54 negatively during the month.

Mangoceuticals(MGRX.US)